Jane Street Group LLC Acquires New Position in Electromed, Inc. (NYSE:ELMD)

Jane Street Group LLC bought a new stake in Electromed, Inc. (NYSE:ELMD - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 23,807 shares of the company's stock, valued at approximately $703,000. Jane Street Group LLC owned 0.28% of Electromed as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Russell Investments Group Ltd. acquired a new position in Electromed during the fourth quarter worth about $37,000. IFP Advisors Inc bought a new stake in Electromed in the fourth quarter valued at approximately $59,000. Quantbot Technologies LP bought a new stake in Electromed in the fourth quarter valued at approximately $99,000. Tower Research Capital LLC TRC boosted its holdings in shares of Electromed by 426.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,055 shares of the company's stock worth $149,000 after buying an additional 4,095 shares in the last quarter. Finally, Bailard Inc. bought a new position in shares of Electromed during the 4th quarter worth approximately $224,000. Institutional investors and hedge funds own 40.82% of the company's stock.

Electromed Price Performance

Shares of Electromed stock traded up $0.17 during trading hours on Thursday, hitting $20.50. 13,100 shares of the company's stock traded hands, compared to its average volume of 72,305. Electromed, Inc. has a 12-month low of $13.74 and a 12-month high of $35.56. The stock has a market capitalization of $171.91 million, a price-to-earnings ratio of 27.33 and a beta of 0.46. The company has a fifty day simple moving average of $22.45 and a 200-day simple moving average of $27.10.

Electromed declared that its Board of Directors has approved a stock repurchase program on Monday, March 10th that authorizes the company to repurchase $5.00 million in shares. This repurchase authorization authorizes the company to buy up to 2.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Wall Street Zen lowered Electromed from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. B. Riley raised Electromed to a "strong-buy" rating in a research report on Thursday, May 15th.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.